异动解读 | Phathom Pharmaceuticals股价大涨6.21% 机构看好公司前景

异动解读08-12

Phathom Pharmaceuticals公司(PHAT)今日股价大涨6.21%,报收12.34美元/股,引发市场广泛关注。

分析人士认为,这一涨幅与机构对该公司前景的看好预期有关。根据最新数据,在参与评级的7家机构中,有86%的机构给予该股买入评级,仅有14%的机构给予持有评级,没有任何机构给予卖出评级。这表明机构普遍看好该公司的长期发展前景。

Phathom Pharmaceuticals是一家临床阶段的生物制药公司,专注于开发和商业化胃肠道疾病的新型疗法。其主打产品vonoprazan是一种口服的小分子钾竞争性酸阻滞剂,可阻断胃酸的分泌,在治疗胃食管反流疾病以及与抗生素联合治疗幽门螺杆菌感染方面具有临床效益。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1199271095?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-12 23:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199271095","market":"hk","top_or_hot":-1,"title":"异动解读 | Phathom Pharmaceuticals股价大涨6.21% 机构看好公司前景","media":"异动解读","content":"<p>Phathom Pharmaceuticals公司(PHAT)今日股价大涨6.21%,报收12.34美元/股,引发市场广泛关注。</p>\n\n<p>分析人士认为,这一涨幅与机构对该公司前景的看好预期有关。根据最新数据,在参与评级的7家机构中,有86%的机构给予该股买入评级,仅有14%的机构给予持有评级,没有任何机构给予卖出评级。这表明机构普遍看好该公司的长期发展前景。</p>\n\n<p>Phathom Pharmaceuticals是一家临床阶段的生物制药公司,专注于开发和商业化胃肠道疾病的新型疗法。其主打产品vonoprazan是一种口服的小分子钾竞争性酸阻滞剂,可阻断胃酸的分泌,在治疗胃食管反流疾病以及与抗生素联合治疗幽门螺杆菌感染方面具有临床效益。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | Phathom Pharmaceuticals股价大涨6.21% 机构看好公司前景</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | Phathom Pharmaceuticals股价大涨6.21% 机构看好公司前景\n</h2>\n\n<h4 class=\"meta\">\n\n2024-08-12 23:08 北京时间&nbsp;&nbsp;&nbsp;<strong>异动解读</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Phathom Pharmaceuticals公司(PHAT)今日股价大涨6.21%,报收12.34美元/股,引发市场广泛关注。\n分析人士认为,这一涨幅与机构对该公司前景的看好预期有关。根据最新数据,在参与评级的7家机构中,有86%的机构给予该股买入评级,仅有14%的机构给予持有评级,没有任何机构给予卖出评级。这表明机构普遍看好该公司的长期发展前景。\nPhathom Pharmaceuticals...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PHAT","symbol_name":"Phathom Pharmaceuticals","start_time":0,"source_url":"","article_id":"1199271095","we_media_id":"1092702339","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199271095","pubTimestamp":1723475301,"sourceInfo":null,"weMediaInfo":{"media_name":"异动解读","introduction":"个股异动一手消息解读","home_visible":1,"id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Phathom Pharmaceuticals公司今日股价大涨6.21%,报收12.34美元/股,引发市场广泛关注。分析人士认为,这一涨幅与机构对该公司前景的看好预期有关。这表明机构普遍看好该公司的长期发展前景。Phathom Pharmaceuticals是一家临床阶段的生物制药公司,专注于开发和商业化胃肠道疾病的新型疗法。其主打产品vonoprazan是一种口服的小分子钾竞争性酸阻滞剂,可阻断胃酸的分泌,在治疗胃食管反流疾病以及与抗生素联合治疗幽门螺杆菌感染方面具有临床效益。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"PHAT":"Phathom Pharmaceuticals"},"translate_title":"Interpretation of the change: Phathom Pharmaceuticals' stock price soared 6.21%, institutions are optimistic about the company's prospects","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHAT":1},"content_text":"Phathom Pharmaceuticals公司(PHAT)今日股价大涨6.21%,报收12.34美元/股,引发市场广泛关注。\n分析人士认为,这一涨幅与机构对该公司前景的看好预期有关。根据最新数据,在参与评级的7家机构中,有86%的机构给予该股买入评级,仅有14%的机构给予持有评级,没有任何机构给予卖出评级。这表明机构普遍看好该公司的长期发展前景。\nPhathom Pharmaceuticals是一家临床阶段的生物制药公司,专注于开发和商业化胃肠道疾病的新型疗法。其主打产品vonoprazan是一种口服的小分子钾竞争性酸阻滞剂,可阻断胃酸的分泌,在治疗胃食管反流疾病以及与抗生素联合治疗幽门螺杆菌感染方面具有临床效益。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199271095"}